Skip to content
Medical Health Aged Care

Huntington’s disease families may benefit from a high-fibre diet

The Florey 2 mins read

In a groundbreaking study, Florey researchers have shown for the first time that high-fibre intake has a positive effect on Huntington’s disease. 

The Florey’s Professor Anthony Hannan, Head of the Epigenetics and Neural Plasticity Group, and Research Co-Lead for the Mental Health Mission, said the results of a study published in Brain Behavior and Immunity indicate that dietary fibre could delay the onset of Huntington’s symptoms. 

There is currently no cure or effective treatment for this devastating disease, which can strike in the prime of life and is always fatal. 

“Huntington’s disease is a debilitating inherited progressive neurodegenerative disorder caused by a faulty gene,” said Professor Hannan, the paper’s senior author. 

“Patients experience worsening motor, cognitive and psychiatric symptoms over many years. The disease also causes gastrointestinal symptoms and in recent years we have discovered disruption to the composition of bacterial populations within the gut.” 

Professor Hannan, Dr Carolina Gubert and their team set out to discover whether dietary interventions could reduce Huntington’s symptoms. 

“Working with a preclinical model, we tested the impact of high, medium and zero levels of dietary fibre consumption. What we found is very exciting. For the first time we’ve shown that high-fibre intake not only enhanced gastrointestinal function, it also improved cognition and behaviour.” 

The study’s lead author, Florey Research Fellow Dr Carolina Gubert, said the study showed that dietary fibre can beneficially modulate Huntington’s disease, and this could occur through the microbiome-gut-brain axis. 

“The gut microbiome in our mouse model of Huntington’s, carrying the human disease gene mutation, responded differently to the high fibre intake compared to the non-Huntington’s mice. This is consistent with our previous discovery that the gut microbiome is altered in Huntington’s disease.” 

Professor Hannan said the results could also have implications for other brain disorders exhibiting dysfunction of the gut-brain axis, such as depression and dementia, and further research will establish if this is the case. 

The Australian Dietary Guidelines are an excellent evidence-based guide for food intake for optimal health, he said.  

The Florey team is now planning to work with Australian and international colleagues to establish a clinical trial to test whether such a high-fibre diet is beneficial in humans.  


About us:

The Florey is Australia’s leading brain research institute with a focus on improving the lives of people with neurological and psychiatric conditions. The Florey’s research missions are centred around dementia, epilepsy, mental health and developing ways to protect and repair the brain. These missions are strengthened by The Florey’s expertise in neurotherapeutics, neuroimaging, synaptic biology and systems neuroscience. With 600 researchers, The Florey is the largest research centre of its kind in the southern hemisphere. 

Find out more about us on our website: www.florey.edu.au


Contact details:

Kathryn Powley

Manager | Media and Communications

[email protected]

0456 666 271

 

Media

More from this category

  • CharitiesAidWelfare, Medical Health Aged Care
  • 17/12/2025
  • 06:00
Leukaemia Foundation

Leukaemia Foundation welcomes South Australian Government commitment to establish dedicated CAR T therapy service

The Leukaemia Foundation has welcomed the announcement by theMalinauskas Labor Government that South Australia is establishing a dedicated CAR T-cell therapy service as a line of treatment for people living with blood cancer – marking a major advancement in cancer care in the State. The new service, expected to commence by mid-2026, will significantly improve access to this highly specialised, life-saving treatment and reduce the need for South Australians to travel interstate for care. Leukaemia Foundation Chief Executive Officer Chris Tanti said the announcement represented a huge win for blood cancer patients and their families. “This is a landmark step…

  • Medical Health Aged Care
  • 17/12/2025
  • 01:10
WW International Inc.

Weight Watchers Launches a Fully Integrated Platform for the GLP-1 Era

A redesigned Weight Watchers experience pairs comprehensive GLP-1 support with personalised nutrition, coaching, community support, and cutting-edge technology to help members meet their weight loss goals and achieve results that lastNEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight Watchers”), the global leader in science-backed weight management, today introduced a new, fully integrated experience bringing together comprehensive support for members on GLP-1 medications, personalised nutrition, behavioural support, coaching, and community within a redesigned app and digital platform. Built for a new era of weight management and long-term health, the new integrated offering delivers coordinated, evidence-based…

  • Medical Health Aged Care
  • 16/12/2025
  • 12:11
Esco Aster Pte. Ltd.

Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform

SINGAPORE–BUSINESS WIRE– Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.